This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval
by Zacks Equity Research
Pfizer (PFE) reports strong second-quarter results. European Commission approves Pfizer and Bristol-Myers' (BMY) medicines.
BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
BioMarin (BMRN) reports mixed second-quarter results with earnings missing estimates but sales beating the same.
Regeneron (REGN) Q2 Earnings Beat on Strong Dupixent Sales
by Zacks Equity Research
Regeneron (REGN) reports impressive Q2 results on the back of growth in both Eylea and Dupixent sales.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Immune Design (IMDZ) reports narrower-than-expected loss and beats revenue estimates in the second quarter of 2018.
Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More
by Zacks Equity Research
Let's see how these pharma/biotech stocks are poised ahead of their scheduled results on Aug 2.
Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Sanofi (SNY) beats earnings but misses on sales in the second quarter of 2018 owing to currency headwinds and struggling diabetes and cardiovascular unit.
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) second-quarter earnings call.
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q2. Lower license and milestone fees result in substantial decrease in year-over-year revenues.
6 European Stocks to Shun on Tapered IMF Outlook
by Sanghamitra Saha
IMF lowered its growth projection for in Germany, France and Italy. Time to avoid these sell-ranked stocks?
Regulus Stock Plunges on Cash Concerns Despite Restructuring
by Zacks Equity Research
Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.
Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale
by Zacks Equity Research
Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
by Zacks Equity Research
Amgen's (AMGN) Repatha significantly reduces LDL-C and non-HDL-C in patients with type II diabetes and hypercholesterolemia or mixed dyslipidemia.
Will Roche's (RHHBY) Acquisition Spree Revive the Top Line?
by Zacks Equity Research
Roche (RHHBY) is looking to boost its portfolio with some strategic acquisitions and we expect further activities on this front.
5 Biotech Stocks Under $10 Worthy of Investors' Attention
by Indrajit Bandyopadhyay
Small biotech stocks are good bets with lower market cap as well as share price.
Alexion-Complement Pharma Tie Up to Treat Neuro Disorders
by Zacks Equity Research
Alexion (ALXN) teams up with Complement Pharma to co-develop its C6 inhibitor, CP010, for neurodegenerative disorders.
Alnylam Reports Positive Data on Lumasiran in Renal Disease
by Zacks Equity Research
Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.
The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street
3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry
by Indrajit Bandyopadhyay
Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well.
5 Biotech Stocks to Boost Your Portfolio's Health This Year
by Kinjel Shah
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio.
The Zacks Analyst Blog Highlights: UnitedHealth, United Technologies, Eni, Sanofi and Discovery
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, United Technologies, Eni, Sanofi and Discovery
Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
by Zacks Equity Research
Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.
Top Research Reports for UnitedHealth, United Technologies & Eni
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), United Technologies (UTX) and Eni (E).
Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data
by Zacks Equity Research
Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
by Zacks Equity Research
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.